Key Highlights
•
In a large real-world study, the MS therapy natalizumab was more effective at reducing relapse rates than anti-CD20 therapies like ocrelizumab and rituximab. This finding helps doctors compare treatments and make more personalized decisions for patients with relapsing-remitting multiple sclerosis.
Source →
•
Poor sleep quality and daytime sleepiness in your 40s are linked to higher levels of Alzheimer’s disease biomarkers in your blood 20 years later. This suggests that improving sleep in midlife could be a way to help reduce the risk of developing Alzheimer’s.
Source →
•
Reeler mice, which have a genetic mutation affecting brain development, performed worse on a test that required them to recognize a new texture by touch. This helps scientists understand how specific genetic changes can impair sensory learning and memory.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
